+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Allergy Relieving Eye Drops Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4895985
  • Report
  • January 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Novartis AG
  • Pfizer
  • Regeneron Pharmaceuticals
  • MORE
Market Overview

Eye Allergy has been increasing in recent years. According to a report by BioMed Research International 2017, the overall prevalence of ocular allergy among school children in Shanghai, China is about 28%. Also, it has been observed that around 15% to 20%of the US population suffers from an ocular allergy. This high prevalence of ocular allergy has increased the demand for allergy eye drops and hence, this factor has acted as a driving factor helping this market grow.
Furthermore, the increasing research and development in eye allergy medication have also brought new innovative medications to the market which are more effective than their predecessors. This factor has also helped this market grow. However, side effects from allergy relieving eye drops, including irritation, headache, and others, have been restraining the growth of this market.

Scope of the Report

An allergic reaction occurs when a person’s immune system reacts to an allergen in the environment, either indoors or outdoors. An allergen is any substance that causes allergy symptoms in sensitive individuals. Allergy relieving eye drops are used to prevent and treat itching of the eyes caused by allergies.
In the report, a detailed analysis of the allergy relieving eye drops market is provided. The market is evaluated by collating revenues generated across segments, categorized by drug class, type, and geography.

Key Market Trends

Antihistamines are Expected to Register a High Growth Rate

Antihistamines block histamine release from histamine-1 receptors and are used to treat the symptoms of an allergic reaction such as edema (swelling), itch, inflammation (redness), and watery eyes.
Eye edema is a very common occurrence. It is primarily caused by Unhealthy cornea prior to surgery. Subsequently, any procedure within the eye (such as cataract, glaucoma or retinal surgery) can cause the cornea to fail and develop edema. As antihistamines effectively treat edema, the market is expected to increase in the forecast period.

North America is expected to dominate the market

North America includes the United States (US), Canada, and Mexico. The United States and Canada have developed healthcare systems and also spend huge amounts in research and development fo the same. As a result, most of the global treatments are available in this region.

According to a Yanqing Feng et al, published in BioMed Research International 2017, among the US households, 34% prevalence of Ocular Allergy symptoms were reported in children. This high prevalence has increased the demands for ocular allergy medications, which is helping the growth of the Allergy Relieving Eye Drops market.

Competitive Landscape

The majority of the allergy relieving eye drops are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market growth.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • Allergan Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Novartis AG
  • Pfizer
  • Regeneron Pharmaceuticals
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Incidence of Ocular Diseases
4.2.2 Increasing Research and Development in Eye Allergy Medication
4.3 Market Restraints
4.3.1 Side Effects from Eye Drops
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 Antihistamines
5.1.2 Non-steroidal anti-Inflammatory Drugs
5.1.3 Vasoconstrictors
5.1.4 Others
5.2 By Type
5.2.1 Seasonal and Perennial Allergic Conjunctivitis
5.2.2 Vernal Keratoconjunctivitis
5.2.3 Atopic Keratoconjunctivitis
5.2.4 Giant Papillary Conjunctivitis
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Allergan Plc
6.1.2 Johnson & Johnson
6.1.3 Pfizer
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Novartis AG
6.1.6 Bausch Health Companies Inc
6.1.7 Regeneron Pharmaceuticals
6.1.8 Santen Pharmaceutical Co

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Allergan Plc
  • Johnson & Johnson
  • Pfizer
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bausch Health Companies Inc
  • Regeneron Pharmaceuticals
  • Santen Pharmaceutical Co
Note: Product cover images may vary from those shown